155 related articles for article (PubMed ID: 38154068)
21. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma.
Shimizu S; Morohashi T; Kanezawa K; Yagasaki H; Takahashi S; Morioka I
Front Pediatr; 2022; 10():908183. PubMed ID: 35859949
[TBL] [Abstract][Full Text] [Related]
22. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study.
Svec P; Elfeky R; Galimard JE; Higham CS; Dalissier A; Quigg TC; Bueno Sanchez D; Han Lum S; Faraci M; Cole T; Pichler H; Benítez-Carabante MI; Horakova J; Gonzalez-Vicent M; Yanir A; Fagioli F; Wölfl M; von der Weid N; Protheroe R; Krivan G; Speckmann C; James B; Avcin SL; Bertrand Y; Verna M; Riha P; Patrick K; Cesaro S; Kalwak K; Bierings M; Büchner J; Mellgren K; Prohászka Z; Neven B; Lankester A; Corbacioglu S
Bone Marrow Transplant; 2023 Feb; 58(2):129-141. PubMed ID: 36333550
[TBL] [Abstract][Full Text] [Related]
23. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation.
Koo J; Ziady AG; Reynaud D; Abdullah S; Luebbering N; Kahn S; Langenberg L; Strecker L; Lake K; Dandoy CE; Lane A; Myers KC; Sabulski A; Good S; Nalapareddy K; Solomon M; Siefert ME; Skala E; Jodele S; Davies SM
Transplant Cell Ther; 2023 Nov; 29(11):704.e1-704.e8. PubMed ID: 37625594
[TBL] [Abstract][Full Text] [Related]
24. Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children.
Schoettler M; Stenger E; Spencer K; Lutterman D; Rumbika S; Jones J; Haight A; Parikh S; Qayed M; Watkins B; Krishnamurti L; Williams KM; Chonat S
Blood Adv; 2023 May; 7(9):1784-1795. PubMed ID: 36075028
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis.
Luo L; Xiong H; Chen Z; Yang L; Sun M; Lu W; Tao F; Wang Z; Li J; Li Z; Tang S
Clin Transl Oncol; 2023 Aug; 25(8):2451-2461. PubMed ID: 36973479
[TBL] [Abstract][Full Text] [Related]
26. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
27. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.
Schoettler M; Duncan C; Lehmann L
Pediatr Transplant; 2019 May; 23(3):e13381. PubMed ID: 30828947
[TBL] [Abstract][Full Text] [Related]
28. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
[TBL] [Abstract][Full Text] [Related]
29. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
Elfeky R; Lucchini G; Lum SH; Ottaviano G; Builes N; Nademi Z; Battersby A; Flood T; Owens S; Cant AJ; Young H; Greener S; Walsh P; Kavanagh D; Annavarapu S; Rao K; Amrolia P; Chiesa R; Worth A; Booth C; Skinner R; Doncheva B; Standing J; Gennery AR; Qasim W; Slatter M; Veys P
Blood Adv; 2020 Jun; 4(11):2418-2429. PubMed ID: 32492158
[TBL] [Abstract][Full Text] [Related]
30. Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.
Fujiwara H; Maeda Y; Sando Y; Nakamura M; Tani K; Ishikawa T; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanimoto M
Transfusion; 2016 Apr; 56(4):886-92. PubMed ID: 26711692
[TBL] [Abstract][Full Text] [Related]
31. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature.
Wirtschafter E; VanBeek C; Linhares Y
Exp Hematol Oncol; 2018; 7():14. PubMed ID: 29977661
[TBL] [Abstract][Full Text] [Related]
33. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease.
Bhunia N; Abu-Arja R; Bajwa RPS; Auletta JJ; Rangarajan HG
Pediatr Blood Cancer; 2019 Oct; 66(10):e27912. PubMed ID: 31264793
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
[TBL] [Abstract][Full Text] [Related]
36. [Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review].
Han W; Han Y; Chen J; Ma X; Chen F; Wu XJ; Qi JQ; Qiu HY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):666-70. PubMed ID: 27587247
[TBL] [Abstract][Full Text] [Related]
37. Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report.
Jarmoliński T; Rosa M; Puziewicz-Zmonarska A; Kałwak K
Transplant Proc; 2020 Oct; 52(8):2544-2547. PubMed ID: 32917392
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab in Transplant-Associated Thrombotic Microangiopathy.
Dhakal P; Giri S; Pathak R; Bhatt VR
Clin Appl Thromb Hemost; 2017 Mar; 23(2):175-180. PubMed ID: 26259912
[TBL] [Abstract][Full Text] [Related]
39. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
Jan AS; Hosing C; Aung F; Yeh J
Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.
Elsallabi O; Bhatt VR; Dhakal P; Foster KW; Tendulkar KK
Clin Appl Thromb Hemost; 2016 Jan; 22(1):12-20. PubMed ID: 26239316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
